Effect of venlafaxine and desvenlafaxine on drug efflux protein expression and biodistribution in vivo

Journal of Pharmaceutical Sciences

Volumn 102, Issue 10, 2013, Pages 3838-3843

  Bachmeier, Corbin ^a   Levin, Gary M ^b   Beaulieu Abdelahad, David ^a   Reed, Jon ^a   Mullan, Michael ^a  

^a ROSKAMP INSTITUTE   (United States)

^b ROSEMAN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Dose response; Drug interactions; Drug transport; Efflux pumps; P glycoprotein

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DESVENLAFAXINE; MULTIDRUG RESISTANCE PROTEIN; RHODAMINE 123; TOPOTECAN; VENLAFAXINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TREATMENT DURATION; UPREGULATION; WHOLE CELL; WILD TYPE;

DOSE-RESPONSE; DRUG INTERACTIONS; DRUG TRANSPORT; EFFLUX PUMPS; P-GLYCOPROTEIN;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; BRAIN; CYCLOHEXANOLS; DRUG INTERACTIONS; INTESTINAL ABSORPTION; INTESTINES; LIVER; MALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; TISSUE DISTRIBUTION; TOPOTECAN; UP-REGULATION;

EID: 84883809462     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23680     Document Type: Article

References (19)

1. Loscher W, Potschka H. 2005. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2(1):86-98.
2. Schinkel AH, Jonker JW. 2003. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Deliv Rev 55(1):3-29.
3. Shugarts S, Benet LZ. 2009. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 26(9):2039-2054.
4. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. 2007. Concise review: Clinical relevance of drug-drug and herb-drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 12(8):927-941.
5. Levin G. 2012. P-glycoprotein: Why this drug transporter may be clinically important. Curr Psychiatry 11(3):38-40.
6. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK. 1999. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104(2):147-153.
7. Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB, Kirch W. 2007. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther 81(5):669-678.
8. Ehret MJ, Levin GM, Narasimhan M, Rathinavelu A. 2007. Venlafaxine induces P-glycoprotein in human Caco-2 cells. Hum Psychopharmacol 22(1):49-53.
9. Bachmeier CJ, Beaulieu-Abdelahad D, Ganey NJ, Mullan MJ, Levin GM. 2011. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Biopharm Drug Dispos 32(4):233-244.
10. Matheny CJ, Ali RY, Yang X, Pollack GM. 2004. Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues. Drug Metab Dispos 32(9):1008-1014.
11. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH. 1992. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52(8):2268-2278.
12. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH. 1999. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59(18):4559-4563.
13. Cohen L. 2009. Desvenlafaxine: Frequently asked questions. Prim Psychiatry 16(12):1-8.
14. Karlsson L, Schmitt U, Josefsson M, Carlsson B, Ahlner J, Bengtsson F, Kugelberg FC, Hiemke C. 2010. Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. Eur Neuropsychopharmacol 20(9):632-640.
15. Charlier C, Pinto E, Ansseau M, Plomteux G. 2002. Venlafaxine: The relationship between dose, plasma concentration and clinical response in depressive patients. J Psychopharmacol 16(4):369-372.
16. Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI. 2009. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 29(1):39-43.
17. Nichols AI, Focht K, Jiang Q, Preskorn SH, Kane CP. 2011. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: A randomized, open-label, two-period, parallel-group, crossover study. Clin Drug Investig 31(3):155-167.
18. Uhr M, Grauer MT, Holsboer F. 2003. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 54(8):840-846.
19. Charlier C, Pinto E, Ansseau M, Plomteux G. 2000. Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Hum Psychopharmacol 15(6):453-459.